Results Wire: US FDA Advisory Committee Supports REPATHA for High Cholesterol, But In Narrower Population Than Proposed – JUN 10, 2015 (EMDAC)
On Wednesday, June 10, 2015, the Endocrinologic and Metabolic Advisory Committee (EMDAC) supported, by a vote of 11-Yes to 4-No, with no abstentions the safety and efficacy of REPATHA (Evolocumab) for injection, submitted by Amgen Inc. (Amgen) for the treatment of high cholesterol (BLA Number 125522). A description of the patient populations that apply to this vote is included in the section of this report "Key Outcomes of Advisory Meeting.” The EMDAC also supported REPATHA, by a vote of 15-Yes and 0-No, with no abstentions for its proposed use to treat patients with homozygous hypercholesterolemia.